Bionectech has created RXSmart, an AI-powered medication-adherence platform specifically designed for elderly patients suffering from Alzheimer’s, dementia, and chronic diseases.
Alzheimer’s affects more than six million Americans. Among its symptoms is significant cognitive decline. This makes it hard for those suffering from the disease to remember to take their medication. In fact, as many as forty percent of those with Alzheimer’s have trouble sticking with their medication schedule.
Not only does this result in worse outcomes for patients, but it also puts a strain on the U.S. healthcare system. The Centers for Medicare & Medicaid Services estimate that medication non-adherence contributes to as much as $300 billion in annual avoidable healthcare costs.
A failure to take medication regularly isn’t just limited to those with Alzheimer’s, either. Patients with chronic diseases — heart failure, COPD, kidney disease — can have trouble remembering, too. Even elderly people who are relatively healthy can easily forget to take medication with any sort of frequency.
That’s why Bionectech created RXSmart.ai. This AI-driven platform includes specialized caregiver support systems. It also has a simple, easy-to-follow interface that’s designed for those suffering from cognitive decline. AI algorithms also adapt to memory-impaired patients. This comprehensive approach aims to support families managing Alzheimer’s care while providing gentle, memory-friendly medication reminders.
Medication adherence is projected to become a nine-billion-dollar market by 2030. With its platform, Bionectech is targeting the 125 million people who battle chronic diseases, as well as the six million Americans living with Alzheimer’s.
Bionectech is in a pilot-testing program in partnership with the University of Maryland School of Medicine. Its team includes experienced healthcare-technology leaders and practicing physicians.
The Company expects to generate its first revenue upon successful completion of pilot programs and commercial deployment.